385 related articles for article (PubMed ID: 7875058)
1. Oral ciprofloxacin versus intravenous therapy with other non-quinolone agents: a study of 291 infections.
Lorian V; Pavletich K
Drugs Exp Clin Res; 1994; 20(5):209-14. PubMed ID: 7875058
[TBL] [Abstract][Full Text] [Related]
2. Sequential intravenous/oral ciprofloxacin as an empiric antimicrobial therapy: results of a Canadian multicenter study. The Canadian Collaborative Investigational Group.
Davis C
Clin Ther; 1994; 16(3):505-21. PubMed ID: 7923317
[TBL] [Abstract][Full Text] [Related]
3. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection.
Iravani A; Klimberg I; Briefer C; Munera C; Kowalsky SF; Echols RM
J Antimicrob Chemother; 1999 Mar; 43 Suppl A():67-75. PubMed ID: 10225575
[TBL] [Abstract][Full Text] [Related]
4. Ciprofloxacin in the treatment of infections at different sites.
Peralta S; Accursio A; Filaci G; Vitale B; D'Aiello G; Scarsi C; Collura D; Rini GB
J Chemother; 1989 Jul; 1(4 Suppl):674-5. PubMed ID: 16312587
[No Abstract] [Full Text] [Related]
5. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
Peloquin CA; Cumbo TJ; Nix DE; Sands MF; Schentag JJ
Arch Intern Med; 1989 Oct; 149(10):2269-73. PubMed ID: 2508586
[TBL] [Abstract][Full Text] [Related]
6. Ciprofloxacin: an update on clinical experience.
Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Becker N; August R
Am J Med; 1987 Apr; 82(4A):381-6. PubMed ID: 3555063
[TBL] [Abstract][Full Text] [Related]
7. Ciprofloxacin in severe infections.
Aswapokee N; Pruksachatvuthi S; Aswapokee P
J Med Assoc Thai; 1990 Jun; 73(6):315-20. PubMed ID: 2230626
[TBL] [Abstract][Full Text] [Related]
8. Follow-up therapy with ciprofloxacin in severe infection, an alternative to parenteral treatment.
Bassaris HP; Chrysanthopoulos CJ; Skouelis AT; Starakis JC
J Chemother; 1989 Jul; 1(4 Suppl):676-7. PubMed ID: 16312588
[No Abstract] [Full Text] [Related]
9. Oral ciprofloxacin in resistant urinary tract infections.
Ryan JL; Berenson CS; Greco TP; Mangi RJ; Sims M; Thornton GF; Andriole VT
Am J Med; 1987 Apr; 82(4A):303-6. PubMed ID: 3555052
[TBL] [Abstract][Full Text] [Related]
10. A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections.
Nicodemo AC; Robledo JA; Jasovich A; Neto W
Int J Clin Pract; 1998 Mar; 52(2):69-74. PubMed ID: 9624783
[TBL] [Abstract][Full Text] [Related]
11. Urinary tract infection. Diabetics and non-diabetic patients.
Akbar DH
Saudi Med J; 2001 Apr; 22(4):326-9. PubMed ID: 11331489
[TBL] [Abstract][Full Text] [Related]
12. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Hansen CR; Pressler T; Høiby N
J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
14. Ciprofloxacin versus cinoxacin in therapy of urinary tract infections. A randomized, double-blind trial.
Goldstein EJ; Kahn RM; Alpert ML; Ginsberg BP; Greenway FL; Citron DM
Am J Med; 1987 Apr; 82(4A):284-7. PubMed ID: 3555049
[TBL] [Abstract][Full Text] [Related]
15. [Antibiotic cover during antineoplastic therapy].
Donno L; Rimoldi R
Minerva Med; 1973 Apr; 64(27):1438-41. PubMed ID: 4575229
[No Abstract] [Full Text] [Related]
16. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis.
Daver NG; Shelburne SA; Atmar RL; Giordano TP; Stager CE; Reitman CA; White AC
J Infect; 2007 Jun; 54(6):539-44. PubMed ID: 17198732
[TBL] [Abstract][Full Text] [Related]
17. Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society.
Louie TJ
CMAJ; 1994 Mar; 150(5):669-76. PubMed ID: 8313286
[TBL] [Abstract][Full Text] [Related]
18. Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections.
Talan DA; Naber KG; Palou J; Elkharrat D
Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S54-66. PubMed ID: 15037329
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic effect of ciprofloxacin as an alternative to injectable antimicrobial therapy.
Powers T; Bingham DH
Am J Hosp Pharm; 1990 Aug; 47(8):1781-4. PubMed ID: 2389785
[TBL] [Abstract][Full Text] [Related]
20. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.
Nix DE; Sands MF; Peloquin CA; Vari AJ; Cumbo TJ; Vance JW; Fracasso JE; Schentag JJ
Am J Med; 1987 Apr; 82(4A):352-6. PubMed ID: 3555060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
